OTCMKTS:CYDY - CytoDyn Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.53 +0.01 (+2.42 %)
(As of 02/22/2019 04:00 PM ET)
Previous Close$0.5175
Today's Range$0.5150 - $0.54
52-Week Range$0.0552 - $0.79
Volume605,091 shs
Average Volume379,750 shs
Market Capitalization$159.72 million
P/E Ratio-1.83
Dividend YieldN/A
Beta0.35
CytoDyn Inc., a clinical-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb treatment substitution trial, Phase IIb extension study, Phase IIb/III pivotal trial, and Phase IIb/III investigative trial for HIV; and Phase II trial for graft-versus-host disease. The company is based in Vancouver, Washington.

Receive CYDY News and Ratings via Email

Sign-up to receive the latest news and ratings for CYDY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CYDY
Previous SymbolNASDAQ:CYDY
CUSIP23283M101
Phone360-980-8524

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.06) per share

Profitability

Net Income$-50,140,000.00

Miscellaneous

Employees6
Market Cap$159.72 million
Next Earnings Date2/25/2019 (Estimated)
OptionableNot Optionable

CytoDyn (OTCMKTS:CYDY) Frequently Asked Questions

What is CytoDyn's stock symbol?

CytoDyn trades on the OTCMKTS under the ticker symbol "CYDY."

How were CytoDyn's earnings last quarter?

CytoDyn Inc (OTCMKTS:CYDY) released its quarterly earnings data on Tuesday, October, 9th. The biotechnology company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.01. View CytoDyn's Earnings History.

When is CytoDyn's next earnings date?

CytoDyn is scheduled to release their next quarterly earnings announcement on Monday, February 25th 2019. View Earnings Estimates for CytoDyn.

What price target have analysts set for CYDY?

1 analysts have issued 12 month price targets for CytoDyn's stock. Their predictions range from $2.00 to $2.00. On average, they expect CytoDyn's share price to reach $2.00 in the next twelve months. This suggests a possible upside of 277.4% from the stock's current price. View Analyst Price Targets for CytoDyn.

What is the consensus analysts' recommendation for CytoDyn?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytoDyn in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CytoDyn.

What are Wall Street analysts saying about CytoDyn stock?

Here are some recent quotes from research analysts about CytoDyn stock:
  • 1. HC Wainwright analysts commented, "We note that leronlimab is a humanized IgG4 monoclonal antibody that blocks CCR5, which functions in both the progression of cancer metastasis and HIV. Our current valuation of leronlimab does not include its application in cancers. Therefore, positive data in cancer indications could drive additional upside to our price target. In the wake of this update, we reiterate our Buy rating and $1.50 price target. Cytodyn is scheduled to host an investment community conference call on the coming Monday to provide a business update. All combo therapy patients to switch to 700 mg dose. The FDA has recognized that the higher dosage of 700 mg in the monotherapy trial had a much higher response rate than the 350 mg dose used in the combination therapy trial, and has agreed to accept safety data from 100 patients in the monotherapy trial with the 700 mg dose." (2/20/2019)
  • 2. According to Zacks Investment Research, "CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed Phase 2 clinical trials with demonstrated antiviral activity in humans and is currently in Phase 3 development. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from seven Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy. " (1/3/2019)

Has CytoDyn been receiving favorable news coverage?

News coverage about CYDY stock has trended positive recently, according to InfoTrie. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. CytoDyn earned a daily sentiment score of 2.7 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next several days.

Who are some of CytoDyn's key competitors?

What other stocks do shareholders of CytoDyn own?

Who are CytoDyn's key executives?

CytoDyn's management team includes the folowing people:
  • Dr. Nader Z. Pourhassan, CEO, Pres & Director (Age 56)
  • Mr. Michael D. Mulholland, CFO, Treasurer & Corp. Sec. (Age 67)
  • Dr. Denis R. Burger, Scientific Consultant (Age 75)
  • Dr. Richard G. Pestell M.B.A., M.D., MBA. M.D., Ph.D., Vice Chairman & Chief Medical Officer
  • Dr. Nitya G. Ray, Chief Technology Officer & Head of Process Sciences, Manufacturing and Supply Chain (Age 66)

How do I buy shares of CytoDyn?

Shares of CYDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CytoDyn's stock price today?

One share of CYDY stock can currently be purchased for approximately $0.53.

How big of a company is CytoDyn?

CytoDyn has a market capitalization of $159.72 million. The biotechnology company earns $-50,140,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. CytoDyn employs 6 workers across the globe.

What is CytoDyn's official website?

The official website for CytoDyn is http://www.cytodyn.com.

How can I contact CytoDyn?

CytoDyn's mailing address is 1111 MAIN STREET SUITE 660, VANCOUVER WA, 98660. The biotechnology company can be reached via phone at 360-980-8524 or via email at [email protected]


MarketBeat Community Rating for CytoDyn (OTCMKTS CYDY)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  108 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  218
MarketBeat's community ratings are surveys of what our community members think about CytoDyn and other stocks. Vote "Outperform" if you believe CYDY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYDY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel